Table 2

Independent lead SNPs that reached genome-wide significance under four different measures of early-phase insulin response

ChrSNPPhenotypePositionLocationGeneEffect/noneffect alleleEffect allele frequencyaImputation qualityaDiscovery cohortReplication cohort
Effect size per allele (%)bSEPEffect size per allele (%)bSEP
3rs115404340insulin3067839179IntronSUCLG2-AS1G/A0.010.4478.50.0983.8E-9−15.70.130.19
9rs505922ΔInsulin136149229IntronABOC/T0.321−6.50.0123.3E-8−7.80.0217.2E-5*
9rs657152IGI136139265IntronABOA/C0.340.988.10.0113.0E-122.70.0170.11
19rs74889068IGI46199363IntronQPCTLA/G0.150.93−8.80.0163.8E-9−2.10.0240.36
3rs115404340IRBMIadj67839179IntronSUCLG2-AS1G/A0.010.4272.50.0923.4E-9−9.80.120.41
19rs74889068IRBMIadj46199363IntronQPCTLA/G0.150.93−10.90.0184.4E-11−4.00.0280.14
  • Threshold for genome-wide significance is 5 × 10−8. Chr, chromosome.

  • * A successful replication, with P value < 0.05.

  • a In the discovery cohort.

  • b β-Coefficient expressed as the percentage difference in the outcome by one copy of the effect allele.